Superworth

Viking Therapeutics price to book ratio VKTX

Market value divided by the book value of the company's net assets, since 2015.

Today, Oct 23, 2026
7.0×
10-year median
3.5×
Against its 10-year history
79th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.9× to 88.6×
Peer median
3.6×

Viking Therapeutics' price to book ratio is 7.0× as of Oct 23, 2026.

That is above its ten-year median of 3.5×, higher than on 79% of days in the last ten years.

Over that time it ranged from 0.9× in Apr 2022 to 88.6× in Feb 2018.

The median for 10 large drugmakers of a similar size is 3.6×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far7.0×4.5×10.2×
20255.9×2.8×6.2×
20245.0×4.9×24.6×
20235.1×2.5×18.0×
20224.8×0.9×4.8×
20211.7×1.7×2.8×
20201.6×1.1×2.2×
20192.1×1.6×2.6×
20181.8×1.7×88.6×
201752.0×2.4×52.2×
20162.3×1.2×4.8×
20152.5×1.5×4.1×

Against its peers

Companies in Drug Manufacturers - General nearest Viking Therapeutics' size, closest first, today.

CompanyPrice to book ratio
VKTXViking Therapeutics7.0×
NRIXNurix Therapeutics2.9×
PBHPrestige Consumer Healthcare1.2×
OGNOrganon3.6×
LQDALiquidia19.6×
HRMYHarmony Biosciences2.1×
ARQTArcutis Biotherapeutics17.8×
INDVIndivior Pharmaceuticalsn/m
ANIPANI Pharmaceuticals2.8×
PAHCPhibro Animal Health4.1×
ANABAnaptysbio138×
Peer median3.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Viking Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.